Home / GU oncology / Prostate / nmCRPC

Prostate → nmCRPC

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — three placebo-controlled phase 3 trials support androgen-receptor pathway inhibition with continued ADT in the conventional-imaging, high-risk population

Who this applies to

Pivotal-trial eligibility and decision boundary

Trial	Eligible population	Key imaging and clinical boundary	Outside direct pivotal evidence
PROSPER	Castration-resistant adenocarcinoma, PSADT ≤10 months, continued ADT¹	CT/MRI and radionuclide bone scan without metastases; seizure history or predisposition was excluded¹.	PSADT >10 months, prior or current conventional-imaging metastases, or seizure-risk population¹.
SPARTAN	PSADT ≤10 months, continued ADT³	Technetium bone scan and CT without distant metastases; pelvic N1 nodes <2 cm below the aortic bifurcation were allowed³.	Conventional-imaging distant metastases or disease outside the trial definition³.
ARAMIS	PSADT ≤10 months, PSA ≥2 ng/mL, ECOG 0–1, continued ADT⁵	CT/MRI and radionuclide bone scan without detectable or prior metastases; pelvic nodes <2 cm below the aortic bifurcation were allowed⁵.	ECOG status outside the study population, conventional-imaging metastases, or disease outside the trial definition⁵.

PSMA-PET-only disease, PSA doubling time >10 months, and failure to meet the castration definition lack direct pivotal-trial efficacy estimates¹³⁵⁷.
Confirm castrate testosterone, PSA kinetics, conventional imaging, prior androgen-receptor pathway inhibitor exposure, falls/fracture risk, blood pressure, cognition, cardiovascular comorbidity, and patient priorities before selecting treatment¹⁰¹¹.

Standard options

Clinical group	Option	Evidence boundary	Typical course
High-risk nmCRPC within a pivotal-trial population	Enzalutamide plus continued ADT¹	PROSPER used conventional-imaging nonmetastatic disease and PSADT ≤10 months¹.	Enzalutamide 160 mg orally daily with continued ADT; duration in the source pack is not stated¹.
High-risk nmCRPC within a pivotal-trial population	Apalutamide plus continued ADT³	SPARTAN used conventional-imaging nonmetastatic disease and PSADT ≤10 months³.	Apalutamide 240 mg orally daily with continued ADT; duration in the source pack is not stated³.
High-risk nmCRPC within a pivotal-trial population	Darolutamide plus continued ADT⁵	ARAMIS used conventional-imaging nonmetastatic disease and PSADT ≤10 months⁵.	Darolutamide 600 mg orally twice daily with food and continued ADT; duration in the source pack is not stated⁵.
Outside the direct pivotal population or unable to use an ARPI	Individualized surveillance, supportive management, or clinical-trial evaluation¹⁰	Do not extrapolate the three phase 3 efficacy estimates to this group¹³⁵.	Individualized¹⁰.

The pivotal trials do not provide a head-to-head comparison or ranking of apalutamide, darolutamide, and enzalutamide¹³⁵.

Therapy sequencing

Disease state	Treatment order	Evidence boundary
High-risk nmCRPC on conventional imaging	Continue ADT → add one of enzalutamide, apalutamide, or darolutamide¹³⁵.	The pivotal trials do not compare the agents head-to-head and require PSADT ≤10 months with conventional-imaging M0 disease¹³⁵.
PSMA-PET-only disease or PSADT >10 months	Individualize surveillance, staging, or trial evaluation⁷¹⁰.	Direct phase 3 treatment-selection evidence is absent for these states¹³⁵.
Conventional-imaging metastasis or progression while castrate	Continue ADT and transition to the mCRPC pathway with prior ARPI exposure documented¹⁰.	Do not presume sequential ARPI benefit from these trials¹³⁵.

Surveillance and treatment de-escalation

Setting	PSA	Imaging	Stop/de-escalate	Re-escalate
On ADT plus ARPI¹³⁵	Every 3 months; testosterone to confirm castration; track PSADT for risk context¹⁰¹¹.	Conventional CT and bone scan every 6–12 months per EAU/NCCN risk-adapted frameworks¹⁰¹¹.	Continue ADT plus the selected ARPI until conventional-imaging metastasis, unacceptable toxicity, or shared decision to stop. Pivotal trials did not define a fixed treatment-stop duration. Hold ARPI for grade ≥3 toxicity; do not stop ADT at M0 progression on PET alone outside trial criteria¹³⁵¹⁰.	Conventional-imaging metastasis while castrate → mCRPC pathway; document prior ARPI agent and duration¹⁰.
Surveillance-only (outside pivotal population)¹⁰	Every 3 months; continue PSADT assessment¹⁰¹¹.	Imaging per PSADT and clinical concern¹⁰¹¹.	No ARPI if PSADT >10 months or PSMA-PET-only disease without conventional metastasis—individualize¹⁷¹⁰.	Rising PSA with new conventional metastases → mCRPC sequencing¹⁰.

PSMA-PET-only disease lacks direct pivotal-trial efficacy estimates; do not use PET alone to stop ADT or ARPI without conventional-imaging confirmation when clinically appropriate⁷¹⁰.

Landmark evidence

The phase 3 studies were placebo-controlled, conventional-imaging nmCRPC trials. The final OS time points differ—median OS in PROSPER and SPARTAN versus 3-year OS in ARAMIS—and must not be compared across trials¹²³⁴⁵⁶.

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
PROSPER, N=1,401	PSADT ≤10 months, continued ADT, CT/MRI plus bone scan without metastases¹	Enzalutamide 160 mg daily + ADT (n=933)¹	Placebo + ADT (n=468)¹	Metastasis-free survival¹	MFS 36.6 vs 14.7 months; HR 0.29 (95% CI 0.24–0.35). Final OS: median 67.0 vs 56.3 months; HR 0.73 (0.61–0.89)¹².	Prior/current metastases and seizure history or predisposition were excluded¹.
SPARTAN, N=1,207	PSADT ≤10 months, continued ADT, conventional-imaging nonmetastatic disease³	Apalutamide 240 mg daily + ADT (n=806)³	Placebo + ADT (n=401)³	Metastasis-free survival³	MFS 40.5 vs 16.2 months; HR 0.28 (0.23–0.35). Final OS: median 73.9 vs 59.9 months; HR 0.78 (0.64–0.96)³⁴.	Pelvic N1 nodes <2 cm were allowed; distant metastases were excluded³.
ARAMIS, N=1,509	PSADT ≤10 months, PSA ≥2 ng/mL, ECOG 0–1, continued ADT, conventional-imaging nonmetastatic disease⁵	Darolutamide 600 mg twice daily with food + ADT (n=955)⁵	Placebo + ADT (n=554)⁵	Metastasis-free survival⁵	MFS 40.4 vs 18.4 months; HR 0.41 (0.34–0.50). Final OS: 3-year OS 83% vs 77%; HR 0.69 (0.53–0.88)⁵⁶.	Pelvic nodes <2 cm were allowed; seizure history was permitted⁵.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
PSA doubling time	Trial risk-enrichment and eligibility factor¹³⁵	—	A PSADT ≤10 months defined the pivotal-trial population for ARPI with continued ADT¹³⁵.	Not an agent-selecting biomarker among enzalutamide, apalutamide, and darolutamide¹³⁵.
Conventional imaging M0 definition	Disease-state classification boundary¹³⁵	—	Phase 3 evidence used conventional CT/MRI and bone imaging to define nonmetastatic disease eligible for treatment¹³⁵.	Pelvic N1 nodes <2 cm were allowed in SPARTAN/ARAMIS; distant metastases exclude this setting³⁵.
PSMA PET	Staging information⁷	Prospective treatment-guidance studies (e.g., PSMACare)⁸	May find occult M1 disease despite negative conventional imaging; does not by itself select among the three ARPIs⁷⁸.	In one retrospective 200-patient high-risk cohort, PSMA PET found M1 disease in 55% despite negative conventional imaging; prospective treatment-guidance value remains unestablished⁷.
Molecular testing	No validated treatment selector among the three ARPIs¹³⁵	Broader panels for later-line planning after progression¹⁰	Does not choose enzalutamide vs apalutamide vs darolutamide on this page¹³⁵.	Pivotal eligibility texts did not report molecular enrollment criteria that select among the three agents¹³⁵.

Upcoming research

Field direction: PSMA-directed approaches in conventional-imaging M0 / PET-positive CRPC and real-world ARPI delivery data may refine nmCRPC counseling, but do not yet replace the three ARPI phase 3 standards⁸⁹¹⁰.

No new practice-changing randomized result was identified in the source pack¹⁰.

Trial or publication	Why it may change care	Evidence status
PSMACare, NCT05849298	Tests lutetium-177 vipivotide tetraxetan alone or with an androgen-receptor pathway inhibitor in PSMA-PET-positive, conventional-imaging-M0 CRPC; the registry permits PET-only M1 disease⁸.	Active, not recruiting; randomized noncomparative phase 2; actual N=49; no posted outcomes⁸.
DAROL	Observational real-world darolutamide experience may inform delivery, but does not compare agents or establish a new treatment standard⁹.	Peer-reviewed observational interim report⁹.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Enzalutamide + ADT versus placebo + ADT, PROSPER	Grade ≥3 AEs: 31% vs 23%; discontinuation due to AEs: 9% vs 6%¹.	Fatigue 33% vs 14%; hypertension 12% vs 5%; falls 11% vs 4%; dizziness 10% vs 4%; falls/nonpathologic fractures combined 17% vs 8%¹.	Contact oncology for marked fatigue, new dizziness, a fall, possible fracture, or blood-pressure concerns; interruption or discontinuation may be needed¹.
Apalutamide + ADT versus placebo + ADT, SPARTAN	Grade 3–4 AEs: 45.1% vs 34.2%; discontinuation due to AEs: 10.6% vs 7.0%³.	Fatigue 30.4% vs 21.1%; hypertension 24.8% vs 19.8%; rash 23.8% vs 5.5%; falls 15.6% vs 9.0%; fracture 11.7% vs 6.5%; hypothyroidism 8.1% vs 2.0%³.	Contact oncology for extensive rash, marked fatigue, a fall or suspected fracture, or blood-pressure concerns; treatment interruption or discontinuation may be needed³.
Darolutamide + ADT versus placebo + ADT, ARAMIS	Grade 3–4 AEs: 24.7% vs 19.5%; discontinuation due to AEs: 8.9% vs 8.7%⁵.	Fatigue 12.1% vs 8.7%; hypertension 6.6% vs 5.2%⁵.	Contact oncology for worsening fatigue, palpitations, chest symptoms, or blood-pressure concerns; treatment interruption or discontinuation may be needed⁵.

Patient counseling and action plan

Contact oncology promptly for a new extensive rash, marked fatigue, a fall or suspected fracture, marked dizziness, new confusion or memory change, palpitations, chest symptoms, or another concerning treatment effect. *** after-hours/urgent-assessment instructions reviewed¹³⁵.
Maintain fall and fracture-risk assessment, blood-pressure monitoring, and thyroid assessment where clinically indicated; treatment holds or discontinuation may be required¹³⁵.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and published rate	Patient action / clinic response
Enzalutamide plus ADT	PROSPER: fatigue 33% vs 14%, hypertension 12% vs 5%, falls 11% vs 4%; falls/nonpathologic fractures combined 17% vs 8%¹.	Monitor blood pressure, falls, dizziness, cognition, and ADT-associated bone/metabolic effects; a fall, suspected fracture, marked dizziness, or chest symptoms needs prompt contact¹.
Apalutamide plus ADT	SPARTAN: rash 23.8% vs 5.5%, falls 15.6% vs 9.0%, fracture 11.7% vs 6.5%, hypothyroidism 8.1% vs 2.0%³.	Monitor skin, thyroid symptoms, blood pressure, falls/fracture risk, and ADT-associated metabolic/bone effects; extensive rash, a fall, suspected fracture, or palpitations needs prompt contact³.
Darolutamide plus ADT	ARAMIS: fatigue 12.1% vs 8.7% and hypertension 6.6% vs 5.2%⁵.	Monitor fatigue, blood pressure, cardiovascular symptoms, and ADT-associated bone/metabolic effects; chest symptoms, palpitations, or worsening fatigue needs prompt contact⁵.

Epic phrase

#nmcrpc

Counseling: Reviewed high-risk nmCRPC as defined in the pivotal trials: castrate testosterone, no metastases on conventional imaging, and PSA doubling time ≤10 months. PSMA-PET-only disease and PSA doubling time >10 months did not have direct pivotal-trial efficacy estimates.
Counseling: In PROSPER, metastasis-free survival was about 37 vs 15 months with placebo (HR 0.29 vs placebo); final median overall survival 67.0 vs 56.3 months with placebo (HR 0.73 vs placebo). SPARTAN apalutamide MFS 40.5 vs 16.2 months with placebo (HR 0.28 vs placebo); final median OS 73.9 vs 59.9 months with placebo (HR 0.78 vs placebo). ARAMIS darolutamide MFS 40.4 vs 18.4 months with placebo (HR 0.41 vs placebo); 3-year OS about 83% vs 77% with placebo (HR 0.69 vs placebo). Trials do not rank agents head-to-head.
Counseling: Reviewed surveillance and de-escalation: PSA every 3 months with conventional imaging every 6–12 months; continue ADT plus ARPI until conventional-imaging metastasis or toxicity; PSMA-PET-only disease lacks pivotal efficacy estimates; conventional metastasis → mCRPC pathway.
Counseling: Reviewed continued ADT plus apalutamide, enzalutamide, or darolutamide as unranked options. Discussed that each placebo-controlled trial improved metastasis-free survival and final overall-survival measures within its own trial; no head-to-head comparison ranks agents.
Counseling: Reviewed sequence: continue ADT → add one ARPI for high-risk conventional-imaging nmCRPC; at conventional-imaging metastatic progression, continue ADT and move to mCRPC sequencing with prior ARPI exposure documented. ***
Counseling: Reviewed treatment-specific safety. Enzalutamide counseling includes fatigue, hypertension, dizziness, falls, and fracture risk; apalutamide counseling includes fatigue, hypertension, rash, falls, fractures, and hypothyroidism; darolutamide counseling includes fatigue and hypertension. Treatment interruption or discontinuation may be needed.
Counseling: Promptly contact oncology for an extensive rash, marked fatigue, marked dizziness, a fall or suspected fracture, new confusion or memory change, palpitations, chest symptoms, or another concerning treatment effect. *** after-hours/urgent-assessment instructions reviewed.
Decision: Continue ADT. *** selects / defers apalutamide / enzalutamide / darolutamide / surveillance / clinical-trial evaluation after shared decision-making.
Labs/NGS: Confirmed castrate testosterone *; PSA doubling time *; conventional imaging ***. Monitor blood pressure; obtain thyroid testing when clinically indicated. Molecular testing does not select among these agents.
Procedures: *** PSMA PET / conventional imaging surveillance / fall and bone-health assessment planned.
Medications: *** continue ADT and start / defer androgen-receptor pathway inhibitor.
Referrals: *** endocrinology / cardiology / geriatric or physical-therapy fall assessment / clinical-trial consultation, as indicated.
Follow-up: *** PSA, testosterone, toxicity, blood-pressure, fall-risk, and imaging follow-up interval.

Edit markdown

Guideline references

Source	Setting-level reference
NCCN Prostate Cancer, version 7.2026	Current US professional guideline reference.
EAU Prostate Cancer guideline	Strong recommendation for continued ADT plus apalutamide, darolutamide, or enzalutamide for the guideline-defined high-risk group.
ESMO Prostate Cancer guideline00042-6/fulltext)	Lists the three agents with continued ADT for high-risk nmCRPC (I,A).
AUA/SUO Advanced Prostate Cancer guideline	Strong, Grade A recommendation for continued ADT plus apalutamide, darolutamide, or enzalutamide in high-risk nmCRPC; imaging surveillance language is expert opinion.

Sources

Changelog

2026-09-22: Explicit Setting×PSA×Imaging surveillance table (PSA q3mo; conventional imaging every 6–12 months; PSADT context); expanded Biomarkers to five-column clinic/emerging format.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added nmCRPC sequencing and an explicit all-ARPI on-treatment monitoring table.
2026-09-21: Created a setting-specific high-risk nmCRPC reference with source-verified PROSPER, SPARTAN, and ARAMIS evidence, trial boundaries, toxicity counseling, and an Epic phrase companion.

Edit evidence markdown

Evidence page